Literature DB >> 8758211

Cadherin expression in melanocytic naevi and malignant melanomas.

G P Cowley1, M E Smith.   

Abstract

An immunocytochemical study has been undertaken of cadherin expression in 11 benign melanocytic naevi and 14 malignant melanomas. Anti-pan-cadherin rabbit antibodies, which recognize multiple cadherin subtypes, demonstrated cadherin expression of moderate or strong intensity in 8 of 11 naevi. Expression was restricted to the more superficial melanocytes which possessed abundant cytoplasm (type A melanocytes). More deeply located melanocytes possessing little cytoplasm (type B melanocytes) or having a spindle cell morphology (type C melanocytes) lacked detectable pan-cadherin expression. The monoclonal antibody HECD-1 detected weak E-cadherin immunostaining in all 11 naevi, expression again being limited, with a single exception, to type A melanocytes. Cadherin immunostaining of moderate or strong intensity was detected by the pan-cadherin antibody in all 14 malignant melanomas. In contrast to naevi, cadherin expression in melanomas frequently extended into the deepest portions of the tumours. E-cadherin immunostaining in malignant melanomas was generally much stronger than that seen in naevi, often being of comparable intensity to the pan-cadherin staining. In summary, cadherins are frequently expressed in melanocytic tumours. In naevi, cadherin expression is related to the degree of melanocytic maturation. Cadherin expression, and particularly E-cadherin expression, tends to be greater in malignant melanomas than in naevi.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8758211     DOI: 10.1002/(SICI)1096-9896(199606)179:2<183::AID-PATH554>3.0.CO;2-W

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  9 in total

1.  Alterations in cadherin and catenin expression during the biological progression of melanocytic tumours.

Authors:  D S Sanders; K Blessing; G A Hassan; R Bruton; J R Marsden; J Jankowski
Journal:  Mol Pathol       Date:  1999-06

2.  Down-regulation of MFG-E8 by RNA interference combined with doxorubicin triggers melanoma destruction.

Authors:  Jing-Yi Zhao; Xue-Lei Ma; Zhi-Mian Li; Rui Deng; Shi-Min Wang; Guo-Bo Shen; Jing Zhang; Feng-Tian Wang; Bing-Lan Zhang; Yu-Quan Wei
Journal:  Clin Exp Med       Date:  2014-03-12       Impact factor: 3.984

Review 3.  Transcriptional control of melanoma metastasis: the importance of the tumor microenvironment.

Authors:  Russell R Braeuer; Maya Zigler; Gabriel J Villares; Andrey S Dobroff; Menashe Bar-Eli
Journal:  Semin Cancer Biol       Date:  2010-12-13       Impact factor: 15.707

Review 4.  Trends in Regenerative Medicine: Repigmentation in Vitiligo Through Melanocyte Stem Cell Mobilization.

Authors:  Stanca A Birlea; Gertrude-E Costin; Dennis R Roop; David A Norris
Journal:  Med Res Rev       Date:  2016-12-28       Impact factor: 12.944

5.  Functional gene expression analysis uncovers phenotypic switch in aggressive uveal melanomas.

Authors:  Michael D Onken; Justis P Ehlers; Lori A Worley; Jun Makita; Yoshifumi Yokota; J William Harbour
Journal:  Cancer Res       Date:  2006-05-01       Impact factor: 12.701

6.  Overexpression of E-cadherin on melanoma cells inhibits chemokine-promoted invasion involving p190RhoGAP/p120ctn-dependent inactivation of RhoA.

Authors:  Isabel Molina-Ortiz; Rubén A Bartolomé; Pablo Hernández-Varas; Georgina P Colo; Joaquin Teixidó
Journal:  J Biol Chem       Date:  2009-03-17       Impact factor: 5.157

7.  CREB inhibits AP-2alpha expression to regulate the malignant phenotype of melanoma.

Authors:  Vladislava O Melnikova; Andrey S Dobroff; Maya Zigler; Gabriel J Villares; Russell R Braeuer; Hua Wang; Li Huang; Menashe Bar-Eli
Journal:  PLoS One       Date:  2010-08-27       Impact factor: 3.240

8.  Loss of AP-2 results in downregulation of c-KIT and enhancement of melanoma tumorigenicity and metastasis.

Authors:  S Huang; D Jean; M Luca; M A Tainsky; M Bar-Eli
Journal:  EMBO J       Date:  1998-08-03       Impact factor: 11.598

9.  AHNAK is downregulated in melanoma, predicts poor outcome, and may be required for the expression of functional cadherin-1.

Authors:  Hilary M Sheppard; Vaughan Feisst; Jennifer Chen; Cris Print; P Rod Dunbar
Journal:  Melanoma Res       Date:  2016-04       Impact factor: 3.599

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.